New gene therapy hopes to restore milestones in rett syndrome

NCT ID NCT05606614

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests a one-time gene therapy called TSHA-102 in females aged 6 to under 22 with classic Rett syndrome. The goal is to see if it is safe and can help them regain or gain new developmental skills like walking or talking. Participants receive the therapy through a spinal injection and are monitored for side effects and improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism, susceptibility to, X-linked 2 Congenital, Hereditary, and Neonatal Diseases and Abnormalities intellectual disability nervous system disorder neurodevelopmental disorder Neurologic Manifestations Pathologic Processes Rett syndrome X-linked disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • CHU St. Justine

    Montreal, Quebec, Canada

  • City of Hope

    Duarte, California, 91010, United States

  • Kennedy Krieger Institute

    Baltimore, Maryland, 21205, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • UC San Diego

    La Jolla, California, 92093, United States

  • UC San Francisco Benioff Children's Hospital

    Oakland, California, 94609, United States

  • UT Southwestern Children's Medical Center

    Dallas, Texas, 75930, United States

  • Washington University, St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.